enGene Therapeutics Inc. Common Stock (ENGN) is a publicly traded Healthcare sector company. As of May 21, 2026, ENGN trades at $1.55 with a market cap of $105.17M and a P/E ratio of 0.70. ENGN moved +5.88% today. Year to date, ENGN is -81.56%; over the trailing twelve months it is -61.67%. Its 52-week range spans $1.40 to $12.25. Analyst consensus is buy with an average price target of $8.69. Rallies surfaces ENGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ENGN shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $1.55 |
| Market Cap | $105.17M |
| P/E Ratio | 0.70 |
| EPS | $2.29 |
| Dividend Yield | 0.13% |
| 52-Week High | $12.25 |
| 52-Week Low | $1.40 |
| Volume | 1.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-117.30M |
| Gross Margin | 0.00% |
12 analysts cover ENGN: 0 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.69.